Register Here
Pre-Meeting Survey
PRN Meeting: July 12, 2023 Jointly provided by the Medical Society of the State of New York, at a Zoom webinar, 7:00 p.m. to 9:00 p.m (EST).
Target Audience:
Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.
Course Director: James F. Braun, DO, President & Program Planner, Physicians' Research Network
Moderator: Ofole Mgbako, MD, Assistant Professor of Medicine and Population Health / Section Chief of Infectious Diseases, NYC H+H/Bellevue Hospital
Guest Speakers and Presentations:
Kaposi Sarcoma and KSHV Transmission in MSM and Other High Risk Groups
Sheena M. Knights, MD
Division of Infectious Diseases and Geographic Medicine
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
At the completion of this educational activity learners will:
1. Know the 3 most common conditions caused by KSHV in patients with HIV.
2. Understand which patients are at highest risk for KSHV-related disease by reviewing KSHV epidemiology and transmission mechanisms.
3. Recognize risk factors for mortality in HIV-associated Kaposi’s sarcoma.
Update on HIV-1 bNAbs for the Prevention, Therapy, and Cure of HIV
Marina Caskey, MD
Professor of Clinical Investigation
The Rockefeller University
New York, NY
At the completion of this educational activity learners will:
1. Know about new anti-HIV broadly neutralizing antibodies in clinical development.
2. Understand results from two prevention efficacy studies (AMP trials) with VRC01, an HIV bNAb.
3. Be aware of recent clinical trials of engineered HIV bNAbs.
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.
The Medical Society of the State of New York designates this live activity for a maximum 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure Statement:
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Program Planner) has no relevant financial relationships to disclose.
- Dr. Ofole Mgbako (Moderator) has no relevant financial relationships to disclose.
- Dr. Sheena M. Knights (Presenter) has no relevant financial relationships to disclose. Dr. Knights will submit her slides in advance for adequate peer review and will support her presentation and clinical recommendations with the best available evidence from the medical literature.
- Dr. Marina Caskey (Presenter) has no relevant financial relationships to disclose. Dr. Caskey will submit her slides in advance for adequate peer review and will support her presentation and clinical recommendations with the best available evidence from the medical literature.
Financial Support:
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare